The Covid-19 pandemic is impacting the global population and economy in unprecedented ways. As venture capital fund managers and corporate investors in non-traded or infrequently traded debt and equity investments exercise their fiduciary duty to report independent and credible fair value information to investors and stakeholders, significant informed judgement will be required. Government actions taken in response to the rapidly changing global health situation due to COVID-19, combined with public market volatility and the potential for a global recession make the judgments reached with respect to fair value at March 31, 2020 very difficult. Response to the crisis from a fair value perspective requires reasoned informed judgment to provide investors, stakeholders, and beneficiaries with decision useful information. Further, the current environment raises questions with respect to applying ASU 2016-01 for corporate venture investors.
Please join us for a further discussion on how to reflect the impact of COVID-19 and current market conditions when estimating and reporting the fair value of early stage investments for the March 31, 2020 quarter end.
Topics
Presenters
CPE Credit
CPE credit will be provided.
Our valuation experts provide valuation services for financial reporting, tax, investment and risk management purposes.
Kroll specializes in assisting clients with the valuation of alternative investments, specifically securities and positions for which there are no "active market" quotations.
Heightened regulatory concerns and vigilance, together with increased investor scrutiny, have led to increased demand for independent expert advice.